Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Phase 3

Completed

Conditions: Exocrine Pancreatic Insufficiency
Cystic Fibrosis

Interventions: Drug: EUR-1008 (APT-1008)
Drug: Placebo

Registration Number: NCT00297167

Lead Sponsor: Forest Laboratories

Brief Summary: The primary efficacy objective of this study is to compare the coefficient of fat absorption (CFA) following oral administration of Aptalis Pharma's (formerly Eurand Pharmaceuticals) pancreatic enzyme product (PEP) capsules and placebo in participants with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI).

Detailed Description: This is a randomized, double-blind, placebo-controlled, 2-treatment, crossover, multicenter trial in participants with CF and EPI. The study consists of a screening period (1 to 14 days), a washout period (2 days), a dose titration/stabilization period (6 to 9 days), a blinded randomized treatment period (6 to 7 days), an open-label normalization period 1 (5 to 14 days), a blinded crossover treatment period (6 to 7 days), followed by an open-label normalization period 2 (7 days). The order of treatments (placebo followed by EUR-1008 \[APT-1008\] or EUR-1008 \[APT-1008\] followed by placebo) will be determined by randomization at the beginning of randomization treatment period only and will be carried through the crossover treatment period. The starting dose will be 1,000 lipase units per kilogram per meal (lipase units/kg/meal), which will be titrated to control symptoms of EPI, with the total dose not exceeding 10,000 lipase units/kg/day.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 34

Inclusion Criteria

Participants with age greater than or equal to (>=) 7 years at the time of enrollment
Participants with weight 70 kg or less and be in an adequate nutritional status as indicated by a body mass index (BMI) >=20 kg/m^2 for ages 18 and above, or a BMI above the twenty fifth percentile for participants aged 7 to 17 years
Participants with confirmed diagnosis of CF who have 2 clinical features consistent with CF, and have either a genotype with 2 identifiable mutations consistent with CF or a sweat chloride concentration that is more than 60 milliequivalent per liter by quantitative pilocarpine iontophoresis
Participants with confirmed diagnosis of EPI who are currently receiving treatment with a commercially available PEP and have documented with a fecal elastase of <100 microgram per gram stool (if no documentation was available, a stool sample was taken at Screening for determination of fecal elastase).
Clinically stable participants with no evidence of acute respiratory disease or any other acute condition
Participants who are willing and able to interrupt current CF treatment for CF-related malabsorption along with any medications that may affect gastric motility or stomach power of hydrogen (pH)
Participants 18 years of age and older had to a) understand the requirements of the study, b) provide written informed consent, c) agree to abide by the study restrictions, and d) return for the required assessments
Participants 7 to 17 years of age must have a parent(s) or legal guardian who provides written informed consent, agree to abide by the study restrictions
Females participants of childbearing potential must have a negative serum pregnancy test at screening and must agree to use adequate birth control during the study

Exclusion Criteria

Participants with fibrosing colonopathy, hyperuricemia or hyperuricosuria
Participants who are allergic to pork or other porcine PEPs
Participants with forced expiratory volume (FEV1) <30 percent of predicted FEV1 at screening
Participants with any acute systemic administration of an antibiotic for any reason in the previous 4 weeks; however, a low stable dose of an antibiotic or chronic treatment with an inhalatory antibiotic is allowed
Participants with hepatic insufficiency as defined by history or presence of ascites or serum albumin level of < 3.0 milligram/deciliter, or a coagulopathy with an international normalized ratio that is greater than 1.7
Participants who have used an acute dose of any steroid in the previous 2 weeks; however, low chronic doses of a steroid is allowed
Participants with history of or current diagnosis of distal ileal obstruction syndrome (DIOS) as evidenced or suggested by constipation, abdominal pain, anorexia, early satiety, recurrent vomiting, and palpable fecal mass on physical examination (the absence of DIOS will be confirmed by an X-ray of the abdomen taken at screening)
Participants with any solid organ transplant or surgery affecting the bowel. Participants with a history of appendectomy and inguinal (non-incarcerated) hernioplasty or meconium ileus without the need for bowel resection could be enrolled. Gastrointestinal-tube-fed patients, in absence of dumping syndrome, were also eligible
Participants with history of or current screening evaluation of hyperglycemia as defined by an 8-hour fasting blood glucose (FBG) of >126 mg/dL, or of CF-related diabetes as determined according to the Cystic Fibrosis Foundation (CFF) Consensus Conference of January 1999 (Section IX Part II), that is: a) FBG >126 mg/dL (7.0 millimoles per liter [mmol/L]) on two or more occasions b)FBG >126 mg/dL (7.0 mmol/L) plus casual (without regard to time of day or last meal consumed) glucose level >200 mg/dL (11.1 mmol/L) c)Casual (previously called random) glucose levels >200 mg/dL (11.1 mmol/L) on two or more occasions with symptoms
Participants using an enzyme preparation in excess of 10,000-lipase units/kg/day
Participants using an immunosuppressive drug
Participants who are expecting an inability to tolerate the washout period and/or the placebo treatment
Participants participating in an investigational study of a drug, biologic, or device not currently approved for marketing, within 30 days of screening visit
Female participants who are pregnant or breastfeeding, or unwilling to use effective birth control during study
Participants with any condition that would, in the investigator's opinion, limit the participant's ability to complete the study

Study & Design

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
EUR-1008 (APT-1008) First, Then Placebo	Placebo	-
EUR-1008 (APT-1008) First, Then Placebo	EUR-1008 (APT-1008)	-
Placebo First, Then EUR-1008 (APT-1008)	EUR-1008 (APT-1008)	-
Placebo First, Then EUR-1008 (APT-1008)	Placebo	-

Primary Outcome Measures

Name	Time	Method
Percent Coefficient of Fat Absorption (CFA%)	Day 3 up to Day 6 of hospital treatment in first and second double-blind intervention periods	Percent CFA was calculated as (\[fat intake - fat excretion\]/fat intake)multiplied by 100, determined in the stools collected during the 72-hour hospitalization period. Mean percent CFA was calculated for Day 3 to Day 6 during hospital treatment in first and second double-blind (DB) intervention periods.

Secondary Outcome Measures

Name	Time	Method
Percent Coefficient of Nitrogen Absorption (CNA%)	Day 3 up to Day 6 of hospital treatment in first and second double-blind intervention periods	Percent CNA was calculated as (\[nitrogen intake-nitrogen excretion\]/nitrogen intake)\*100, determined in the stools collected during the 72-hour hospitalization period. Nitrogen intake was calculated as protein intake/6.2. Nitrogen excretion was measured as total fecal nitrogen. Mean percent CNA was calculated for Day 3 to Day 6 during hospital treatment in first and second double-blind intervention periods.
Percentage of Stool Categorized as Per Consistency	Day 3 up to Day 6 during first and second double-blind intervention periods	Stool consistency was categorized as hard, formed/normal, soft, watery, or overt diarrhea. Percentage of stools of a specific consistency for each participant at first and second double-blind intervention periods was calculated. Mean percentage of stool consistency during the collection period (Day 3 to Day 6 in first and second intervention periods) for total participants was summarized.
Lipid Levels	End of treatment (Day 6 during first and second double-blind intervention periods)	Lipid levels were reported for total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) from fasted blood and urine samples. Mean lipid levels for Day 6 during first and second double-blind intervention periods were calculated.
Vitamin E Levels	End of treatment (Day 6 during first and second double-blind intervention periods)	Mean Vitamin E levels for Day 6 during first and second double-blind intervention periods were calculated.
Vitamin A Levels	End of treatment (Day 6 during first and second double-blind intervention periods)	Mean Vitamin A levels for Day 6 during first and second double-blind intervention periods were calculated.
Mean Daily Number of Stools	Day 3 up to Day 6 during first and second double-blind intervention periods	Mean daily number of stools of each participant was calculated from frequency of stools by the participant per day. Mean daily number of stools during the collection period (Day 3 to Day 6 in first and second double-blind intervention periods) for total participants was summarized.
Mean Number of Abdominal Symptoms	Day 3 up to Day 6 during first and second double-blind intervention periods	Abdominal symptoms included abdominal pain, flatulence and bloating. Symptoms were classified by severity as mild (no impairment of daily activities), moderate (slight impairment of daily activities), or severe (unable to perform daily activities). Mean number of symptom of specific severity per day for each participant was calculated. Mean number of symptoms per day was calculated for Day 3 to Day 6 in first and second double-blind intervention periods for total participants.